iShares' URTH or Schwab's SCHF: Which International ETF Is the Better Buy?

SCHF offers a much lower 0.03% expense ratio and higher 2.9% dividend yield than URTH’s 0.24% fee and 1.4% yield, making it the cheaper income-oriented choice. Over the last year through June 12, 2026, SCHF outperformed URTH 30.2% to 23.1%, though URTH still led over five years with $1,720 growth on $1,000 versus $1,592 for SCHF. The article’s main takeaway is portfolio construction: URTH still carries heavy U.S. tech exposure, while SCHF is a cleaner developed ex-U.S. diversifier.

Analysis

The cleaner read here is not that "international" is winning outright, but that factor exposure is changing underneath the surface. URTH is effectively a concentrated U.S. megacap growth proxy wrapped in global branding, so the real beneficiary of incremental inflows is still the same small set of AI-capex leaders and their semiconductor/tooling ecosystem. SCHF, by contrast, is a higher-dividend, lower-duration basket that should outperform when U.S. rates stay elevated or the dollar weakens further, because its cash flows are less dependent on long-duration multiple expansion.

The second-order effect is that SCHF is a better hedge against U.S. equity crowding than a broad developed-market bet. If the market’s leadership narrows or U.S. tech stumbles on any pause in AI spending, regulation, or a valuation reset, URTH likely de-rates faster than its headline global label suggests. That makes the current gap in 1-year performance less a signal of structural U.S. dominance and more a reflection of the same momentum trade being repackaged into an ETF wrapper.

For the named constituents, the implication is mixed. NVDA, AAPL, and MSFT continue to benefit from being embedded in multiple “diversified” products, which mechanically supports passive bid and dampens near-term downside, while ASML is the cleaner international tech lever because it sits in both the AI supply chain and a non-U.S. domicile. NFLX is largely irrelevant to the fund-level thesis, which underscores that the article’s main signal is factor concentration, not broad-stock picking.

The contrarian view is that SCHF’s outperformance may not persist if the dollar stabilizes or U.S. real yields fall, because the relative valuation gap versus U.S. large caps could quickly become the dominant driver again. In that sense, the trade is less "buy international" and more "own the assets that benefit from mean reversion in U.S. concentration." The consensus may be underestimating how much of URTH’s return profile is simply an expensive wrapper around the same U.S. winners investors already own.

Key Decisions for Investors

• Rotate incremental global equity exposure from URTH into SCHF over 2-4 weeks; better risk/reward if your book is already U.S.-heavy, with lower fee drag and less U.S. mega-cap overlap.
• Pair trade: long SCHF / short URTH for a 3-6 month relative-value view on U.S. concentration risk and multiple compression in megacap tech; stop if U.S. growth leadership broadens materially.
• For tech exposure, prefer ASML over URTH as the cleaner non-U.S. AI-capex beneficiary; hold as a 6-12 month structural long versus a basket that still embeds U.S. concentration.
• If you need hedge-like diversification, use SCHF instead of broad developed-market products; it should be more responsive to continued dollar weakness and less correlated with domestic momentum.
• Sell covered calls on URTH into strength if already long, monetizing the embedded megacap concentration premium while limiting downside if the AI complex pauses.